Mixed feelings.
Lot's of 'we are bullish' statements, but very scant on actual expectations of FY 2025 figures.
Probably the most important takeaways for me:
No current purchasers of Febridex in Australia
Good expansion of Febridex into the USA Student health market
Progress made on CLIA waiver
Progress made on re-imbursement coding - why that wasn't done before launch is baffling tbh.
I think it all depends on the Febridex uptake in the next FY (obviously) to see whether we will be 100% reliant on IP deals to keep the doors open.
If it takes off - so will the SP. It's that simple.
Overall - 6.5/10
Lots of bones, not too much meat.
Ann: Q4 FY24 Investor Presentation, page-4
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 3.9¢ | $100.6K | 2.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 623990 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 298309 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| LDX (ASX) Chart |